Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
First Claim
1. A method for treating urinary incontinence, comprising administering to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R,R)-glycopyrrolate (3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide), or a pharmaceutically acceptable salt thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (R, R)-glycopyrrolate. The method comprises administering a therapeutically effective amount of enantiomerically enriched (R, R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, substantially free of the (S, S)-glycopyrrolate enantiomer. Pharmaceutical compositions for the treament of urinary incontinence comprising enantiomerically enriched (R, R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.
144 Citations
42 Claims
- 1. A method for treating urinary incontinence, comprising administering to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R,R)-glycopyrrolate (3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide), or a pharmaceutically acceptable salt thereof.
- 13. A method for treating bladder detrusor muscle instability, said method comprising administering to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof.
- 15. A pharmaceutical composition, comprising enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 22. A pharmaceutical composition, comprising (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, substantially free of (S,S)-glycopyrrolate, and a pharmaceutically acceptable carrier.
- 29. A pharmaceutical unit dosage form, which comprises enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a tablet.
-
32. A pharmaceutical unit dosage form which comprises substantially enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a tablet.
- 33. A pharmaceutical unit dosage form, which comprises enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a soft elastic gelatin capsule.
-
36. A pharmaceutical unit dosage form which comprises substantially enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a soft elastic gelatin capsule.
-
37. A mixture of (R,R)-glycopyrrolate and (S,S-glycopyrrolate enantiomers, or pharmaceutically acceptable salts thereof, wherein the ratio of (R,R-glycopyrrolate to (S,S)-glycopyrrolate is greater than 1:
- 1.
-
38. A mixture of (R,R)-glycopyrrolate and (S,S)-glycopyrrolate enantiomers, or pharmaceutically acceptable salts thereof, wherein the (R,R)-glycopyrrolate enantiomer comprises at least 85% by weight of the total mixture.
- 39. A kit for treating urinary incontinence, wherein said kit comprises a pharmaceutical composition comprising enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering said composition for treating urinary incontinence while reducing or eliminating concomitant liability of adverse effect.
- 41. A kit for treating urinary incontinence, wherein said kit comprises a pharmaceutical composition comprising substantially enantiomerically enriched (R,R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering said composition for treating urinary incontinence while reducing or eliminating concomitant liability of adverse effects.
Specification